untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:26:02Z</responseDate>
<request identifier=oai:HAL:hal-01239807v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01239807v1</identifier>
<datestamp>2017-12-22</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:HCL</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:IRSET-CCII</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:IRSET-1</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Severe Pulmonary Hypertension Associated with COPD: Hemodynamic Improvement with Specific Therapy</title>
<creator>Girard, Anne</creator>
<creator>Jouneau, Stéphane</creator>
<creator>Chabanne, Céline</creator>
<creator>Khouatra, Chahéra</creator>
<creator>Lannes, Morgane</creator>
<creator>Traclet, Julie</creator>
<creator>Turquier, Ségolène</creator>
<creator>Delaval, P.</creator>
<creator>Cordier, J.-F.</creator>
<creator>Cottin, Vincent</creator>
<contributor>Service de pneumologie ; Hôpital Pontchaillou - CHU Pontchaillou [Rennes]</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de cardiologie et maladies vasculaires ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou - CHU Pontchaillou [Rennes]</contributor>
<contributor>Université Claude Bernard Lyon 1 (UCBL)</contributor>
<contributor>Hôpital Louis-Pradel [Lyon] ; Université Claude Bernard Lyon 1 (UCBL) - Hospices Civils de Lyon - Hôpital Louis-Pradel</contributor>
<contributor>Service de Pneumologie ; Hôpital Louis-Pradel</contributor>
<description>International audience</description>
<source>Respiration; International Review of Thoracic Diseases</source>
<identifier>hal-01239807</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01239807</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01239807</source>
<source>Respiration; International Review of Thoracic Diseases, 2015, 90 (3), pp.220--228. 〈10.1159/000431380〉</source>
<identifier>DOI : 10.1159/000431380</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1159/000431380</relation>
<identifier>PUBMED : 26277885</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/26277885</relation>
<language>en</language>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>BACKGROUND: There is no recommendation for treating pulmonary hypertension (PH) when associated with chronic obstructive pulmonary disease (COPD). OBJECTIVE: To evaluate the effect of PH-specific therapy in patients with COPD. METHODS: All successive patients with severe PH [mean pulmonary arterial pressure (mPAP) ≥35 mm Hg] and COPD, who received specific PH medication and who underwent right heart catheterization at baseline and after 3-12 months of treatment, were analyzed from a prospective database. RESULTS: Twenty-six patients were included with a median follow-up of 14 months. Mean forced expiratory volume in 1 s was 57 ± 20% of predicted, and mean forced expiratory volume in 1 s/forced vital capacity was 47 ± 12%. Dyspnea was New York Health Association classification stage (NYHA) II in 15%, NYHA III in 81% and NYHA IV in 4%. First-line treatments were endothelin receptor antagonists in 11 patients, phosphodiesterase-5 inhibitors in 11 patients, calcium blocker in 1 patient, combination therapy in 3 patients including 2 with a prostanoid. After 6 ± 3 months, pulmonary vascular resistance decreased from 8.5 ± 3 to 6.6 ± 2 Wood units (p extless 0.001), with significant improvement of cardiac index from 2.44 ± 0.43 to 2.68 ± 0.63 liters × min × m-2 (p = 0.015) and mPAP from 48 ± 9 to 42 ± 10 mm Hg (p = 0.008). There was no significant difference in dyspnea, 6-min walking distance, echocardiographic parameters or N-terminal pro-brain natriuretic peptide levels. There was no significant difference in arterial oxygen saturation after 3-12 months of treatment. CONCLUSIONS: Specific PH medications may improve hemodynamic parameters in COPD patients with severe PH. Appropriate prospective randomized studies are needed to evaluate the potential long-term clinical benefit of treatment</description>
<date>2015</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
